VC: Aerovance lands $60M in VC

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Aerovance
Berkeley, CA

$60M
Third

Clarus Ventures

The funding will be used to get the company's two lead products through proof-of-concept studies.

Nanosphere
Northbrook, IL

$57M
Fourth

Bain Capital

The capital will be used to commercialize a new and more efficient method for gene and protein testing.

MacroGenics
Rockville, MD

$45M
Third

Ventures West

MacroGenics' lead product is slated for a Phase II/III trial to begin later this year for Type 1 diabetes. The company also has earlier-stage prospects for cancer and autoimmune diseases.

Avidia
Mountain View, CA

$43.8M
Third

Skyline Ventures

Much of the money will go to fund studies of an inhibitor of interleukin 6 for the treatment of inflammation and autoimmune disease and an inhibitor of IgE.

Viron Therapeutics
Canada

$20M
First

Canadian Medical Discoveries Fund

The funds will finance the company's operations through to the end of 2008.

Onyvax
London, England

$14.7M
Third

3i and SR One

The funds raised will be used to advance the development of Onyvax-P, the firm's lead product for the treatment of prostate cancer.

D-Pharm
Israel

$10M

Clal Biotechnology Industries, Israel Healthcare Ventures and Pitango Venture Capital

D-Pharm is currently in Phase IIb with an experimental drug for strokes and is also developing therapies for brain disorders and epilepsy.